AI to help heart patients avoid bleeding risks after stents

NCT ID NCT05369442

Recruiting now Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 1,300 people with coronary artery disease who have a high risk of bleeding after getting a heart stent. Researchers will use artificial intelligence to analyze which blood-thinning drugs and treatment lengths work best to prevent serious bleeding and heart attacks. The goal is to create a safer, more personalized approach to antiplatelet therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antiplatelet drugs
What this could lead to: If successful, this could lead to a personalized antiplatelet treatment plan that reduces bleeding risk after heart stent procedures.
What could go wrong: This is an observational study, not a controlled trial, so it can show patterns but not prove which treatment is best. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

West China Hospital, Sichuan University
RECRUITING

Sichuan, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.